Global Market Bulletin
  • Home
  • Stock Market News
  • Investing
  • Economy
  • CEO Interviews
  • Contact Us
No Result
View All Result
SUBSCRIBE
Global Market Bulletin
  • Home
  • Stock Market News
  • Investing
  • Economy
  • CEO Interviews
  • Contact Us
No Result
View All Result
Global Market Bulletin
No Result
View All Result
Home Stock Market News

Top 10 Stocks That Could Make You a Millionaire Over the Next 3 Years

by Global Market Bulletin
June 28, 2026
in Stock Market News
0
Top 10 Stocks That Could Make You a Millionaire Over the Next 3 Years

Top 10 Stocks That Could Make You a Millionaire Over the Next 3 Years

378
SHARES
821
VIEWS
Share on FacebookShare on Twitter

9. UnitedHealth Group Incorporated (NYSE:UNH)

UnitedHealth Group Incorporated (NYSE:UNH) ranks No. 9 among the Top 10 Stocks That Could Make You a Millionaire Over the Next 3 Years, and unlike the usual high-flying technology names, this one brings a different kind of story to the table. Trading at $427.89, with the stock up 2.97%, UnitedHealth Group Incorporated (NYSE) is one of the largest and most important healthcare stocks in the world. The company is supported by 130 hedge fund holders, showing that institutional investors continue to view it as a major player in the healthcare sector. Over the past 30 days, UnitedHealth Group Incorporated (NYSE:UNH) has gained more than 10% and is now trading close to its 52-week high, helped by positive analyst upgrades, improving sentiment, and a proposed FTC settlement that appears to have eased some investor concerns. For investors looking for healthcare stocks to buy, defensive growth stocks, managed care stocks, long-term compounders, and blue-chip stocks with upside potential, UnitedHealth Group Incorporated (NYSE:UNH) remains one of the most important names to watch.

You might also like

Could ARS Pharmaceuticals (SPRY) Disrupt the Emergency Allergy Treatment Market?

Is Lexeo Therapeutics (LXEO) a Good Gene Therapy Stock for Long-Term Growth?

Is Sagimet Biosciences (SGMT) a Promising Biotech Stock to Buy Before Its Next Catalyst?

The bullish case for UnitedHealth Group Incorporated (NYSE:UNH) became stronger after Bank of America Securities raised its price target on the stock from $450 to $475 on June 24 while maintaining a Buy rating. The firm said its positive view was based on growing confidence in cost trends heading into Q2 earnings. That detail is important because in the managed care industry, medical cost trends can make or break investor sentiment. If costs rise faster than expected, margins can come under pressure. If pricing remains disciplined and medical costs stay manageable, the market often rewards healthcare insurers with higher valuation multiples. Bank of America pointed to a higher valuation multiple and a “continuous positive outlook on trend” as key reasons behind its more optimistic target. In simpler terms, Wall Street is becoming more comfortable with UnitedHealth Group Incorporated (NYSE:UNH) again, and that confidence can matter a lot for a stock that has already started to regain momentum.

UnitedHealth Group Incorporated (NYSE:UNH) also received support earlier in June when Leerink analyst Whit Mayo raised the firm’s price target on the stock from $400 to $420 while maintaining a Buy rating. The analyst cited improved margins as one of the key drivers behind the upgrade. During the first quarter, UnitedHealth Group Incorporated (NYSE:UNH) saw its medical care ratio improve to 83.9%, compared to 84.8% a year earlier. That was also better than analyst expectations of 85.7%, helped by disciplined pricing and favorable reserve development. For readers who do not follow healthcare finance closely, the medical care ratio is a crucial profitability metric. A lower ratio generally means the company is spending a smaller share of premium revenue on medical costs, which can support better margins. That makes the improvement especially important for investors watching UnitedHealth Group Incorporated (NYSE:UNH) as a potential long-term stock market winner.

UnitedHealth Group Incorporated (NYSE:UNH) operates through UnitedHealthcare, Optum Insight, Optum Health, and Optum Rx, giving the company a massive footprint across insurance, healthcare services, pharmacy benefits, data analytics, and care delivery. That diversified structure is one reason UnitedHealth Group Incorporated (NYSE:UNH) often stands out among healthcare stocks. It is not just an insurer. It is a healthcare ecosystem company with exposure to multiple profit pools across the industry. In a market where investors are still hunting for recession-resistant stocks, healthcare compounders, and stocks with durable earnings growth, UnitedHealth Group Incorporated (NYSE:UNH) offers a more stable route to wealth creation compared to many speculative growth names. It may not carry the same headline excitement as an AI stock or EV stock, but its scale, margin recovery, and analyst support make it a serious contender for investors looking at the next three years.

Click next to see the following stock...

Page 2 of 5
Prev123...5Next
Tags: Daily NewsletterEli Lilly and Company (NYSE:LLY)HeadlineNASDAQ:NFLXNASDAQ:TSLANetflix Inc. (NASDAQ:NFLX)NYSE:LLYNYSE:UNHNYSE:VTesla Inc. (NASDAQ:TSLA)Top 10 Stocks That Could Make You a Millionaire Over the Next 3 YearsUnitedHealth Group Incorporated (NYSE:UNH)Visa Inc. (NYSE:V)Yahoo Finance
Share151Tweet95

Global Market Bulletin

Global Market Bulletin is a leading provider of stock market updates, economic news, and personalized investing guides. Our team brings you the latest global financial information to help you make smart investment decisions. About the Editorial Team Our editorial team consists of financial experts and seasoned market analysts who bring decades of experience to our coverage. With a commitment to unbiased reporting, our team ensures that every article is backed by thorough research and delivers accurate financial insights.

Recommended For You

Could ARS Pharmaceuticals (SPRY) Disrupt the Emergency Allergy Treatment Market?

by Global Market Bulletin
July 18, 2026
0
Could ARS Pharmaceuticals (SPRY) Disrupt the Emergency Allergy Treatment Market?

We recently published our article 5 Stocks Under $10 Analysts Believe Could Soar 200%. To read the full story, you can go directly to 10 Stocks Under $10...

Read moreDetails

Is Lexeo Therapeutics (LXEO) a Good Gene Therapy Stock for Long-Term Growth?

by Global Market Bulletin
July 18, 2026
0
Is Lexeo Therapeutics (LXEO) a Good Gene Therapy Stock for Long-Term Growth?

We recently published our article 5 Stocks Under $10 Analysts Believe Could Soar 200%. To read the full story, you can go directly to 10 Stocks Under $10...

Read moreDetails

Is Sagimet Biosciences (SGMT) a Promising Biotech Stock to Buy Before Its Next Catalyst?

by Global Market Bulletin
July 18, 2026
0
Is Sagimet Biosciences (SGMT) a Promising Biotech Stock to Buy Before Its Next Catalyst?

We recently published our article 5 Stocks Under $10 Analysts Believe Could Soar 200%. To read the full story, you can go directly to 10 Stocks Under $10...

Read moreDetails

What Makes SharpLink (SBET) a High-Risk Stock Investors Cannot Ignore?

by Global Market Bulletin
July 18, 2026
0
What Makes SharpLink (SBET) a High-Risk Stock Investors Cannot Ignore?

We recently published our article 5 Stocks Under $10 Analysts Believe Could Soar 200%. To read the full story, you can go directly to 10 Stocks Under $10...

Read moreDetails

Is Omeros (OMER) a Smart Biotech Investment Before Its Next Major Catalyst?

by Global Market Bulletin
July 18, 2026
0
Is Omeros (OMER) a Smart Biotech Investment Before Its Next Major Catalyst?

We recently published our article 5 Stocks Under $10 Analysts Believe Could Soar 200%. To read the full story, you can go directly to 10 Stocks Under $10...

Read moreDetails

Browse by Category

  • CEO Interviews
  • Economy
  • Investing
  • Stock Market News
  • Uncategorized

QUICK LINKS

  • Stock Market News
  • Investing
  • Economy
  • Contact Us
  • About Global Market Bulletin
  • Editorial Policy – Global Market Bulletin
  • Our Editorial Team

RECENT POSTS

  • Could ARS Pharmaceuticals (SPRY) Disrupt the Emergency Allergy Treatment Market?
  • Is Lexeo Therapeutics (LXEO) a Good Gene Therapy Stock for Long-Term Growth?
  • Is Sagimet Biosciences (SGMT) a Promising Biotech Stock to Buy Before Its Next Catalyst?

GET EMAIL MARKET UPDATES

Subscribe to our mailing list to receives daily updates direct to your inbox!
  • Privacy Policy
  • Terms and Conditions

© 2022 Global Market Bulletin. All Rights Reserved.

No Result
View All Result
  • Home
  • Stock Market News
  • Investing
  • Economy

© 2022 Global Market Bulletin. All Rights Reserved.

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?